Skip to main content
. 2020 Apr 20;10:44. doi: 10.1186/s13613-020-00656-w

Table 1.

Population characteristics

All patients
(n = 158)
Without MAKE-360
(n = 21)
With MAKE-360
(n = 120)
Women/men 24.1/75.9 2/19 33/87
Weight (kg) 77 [65; 90] 74 [65; 85] 78 [66; 90]
Height (cm) 170 [165; 178] 178 [169; 180.5] 170 [165; 177]
Body mass index (kg/m2) 26.2 [22.9; 30] 24.4 [20.6; 26.4] 26.8 [23.8; 30.5]
Age (years) 59 [47; 66] 49 [39; 56] 60 [49.5; 66.5]
Length of ICU stay (days) 20.5 [12; 39] 19 [14; 39] 21 [12; 38.5]
SAPS-II at ICU admission 54.5 [39; 66] 39 [21; 60] 55.5 [40.5; 68]
SOFA at ICU admission 9 [7; 12] 8 [5; 10] 9.5 [7; 12]
 Respiratory item 1 [0; 2] 1 [0; 2] 2 [1; 3]
 Neurologic item 0 [0; 1] 0 [0; 2] 0 [0; 1]
 Hemodynamic item 4 [3; 4] 4 [2; 4] 4 [3; 4]
 Liver item 1 [0; 2] 1 [0; 2] 1 [0; 2]
 Kidney item 1 [0; 2] 0 [0; 1] 1 [0; 2]
 Coagulating item 1 [0; 2] 0 [0; 2] 1 [0; 2]
Known comorbidities
 Previous myocardial infarction 45 (28.5) 2 (9.5) 37 (30.8)
 Chronic cardiac failure 93 (58.9) 7 (33.3) 77 (64.2)
 Peripheral vascular disease 19 (12) 1 (4.8) 16 (13.3)
 Dementia 1 (0.6) 0 (0) 1 (0.8)
 Cerebrovascular disease 20 (12.7) 1 (4.8) 18 (15)
 Chronic respiratory disease 29 (18.4) 2 (9.5) 24 (20)
 Connectivitis 6 (3.8) 3 (14.3) 2 (1.7)
 Ulcers 11 (7) 0 (0) 10 (8.3)
 Chronic liver disease 3 (1.9) 0 (0) 3 (2.5)
 Diabetes 44 (27.8) 3 (14.3) 38 (31.7)
 Hemiplegia 2 (1.3) 0 (0) 2 (1.7)
 Moderate-to-severe renal failure 34 (21.5) 0 (0) 32 (26.7)
 Solid tumor 6 (3.8) 0 (0) 6 (5)
 Leukemia 1 (0.6) 1 (4.8) 0 (0)
 Lymphoma 1 (0.6) 0 (0) 1 (0.8)
 AIDS 0 0 0
 Hypertension 62 (39.2) 3 (14.3) 53 (44.2)
 Active smoking 23 (14.6) 4 (19) 17 (14.2)
 Dyslipidemia 50 (31.6) 3 (14.3) 41 (34.2)
 Alcoholism 10 (6.3) 3 (14.3) 6 (5)
Duration of CBP (min)* 148.5 [109; 210] 140 [89; 177] 155 [116; 220]
 No CBP 90 (60) 11 (55) 71 (62.8)
 CBP ≤ 140 min 28 (18.7) 4 (20) 20 (17.7)
 CBP > 140 min 40 (25.3) 5 (25) 22 (19.5)
Duration of aortic clamping (min)* 81.5 [56.5; 114.5] 102.5 [55; 127] 81 [56; 111]
Place of cannulation
 In ICU 29 (18.4) 1 (4.8) 22 (18.3)
 Operative bloc 116 (73.4) 18 (85.7) 88 (73.3)
 Other 13 (8.2) 2 (9.5) 10 (8.3)
Cannulation site
 Femoro-femoral 66 (41.8) 10 (47.6) 45 (37.5)
 Other 92 (58.2) 11 (52.4) 75 (62.5)
Time from ICU admission to cannulation (days) 1 [1; 1] 1 [1; 1] 1 [1; 2]
ECMO duration (days) 7.5 [4; 12] 6 [3; 8] 8 [5; 13]
Recannulation 31 (19.6) 3 (14.3) 28 (23.3)
Mechanical ventilation at cannulation 123 (77.8) 16 (76.2) 92 (76.7)
SOFA at cannulation 9 [7; 12] 9 [6; 10] 9 [7; 12]
 Respiratory item 2 [1; 3] 2 [1; 2] 2 [1; 3]
 Neurological item 0 [0; 4] 0 [0; 4] 0 [0; 4]
 Hemodynamic item 4 [4; 4] 4 [4; 4] 4 [4; 4]
 Liver item 0 [0; 2] 1 [0; 2] 0 [0; 2]
 Kidney item 1 [0; 2] 0 [0; 1] 1 [0; 2]
 Coagulation item 0 [0; 1] 0 [0; 1] 0 [0; 1]
 SOFA without hemodynamic score 5 [3; 8] 5 [3; 6] 5 [3; 8]
Biological features at cannulation
 Lactate (mmol/l) 3 [2.2; 5.4] 3.1 [3; 6.1] 3 [2.2; 4.5]
 AST (UI/l) 93.5 [47; 262] 94 [60; 437] 93.5 [45.5; 276.5]
 ALT (UI/l) 68 [35; 216] 68 [36; 289] 68 [34.5; 186]
 Platelets count (g/l) 163 [123; 228] 187 [104; 232] 162 [123; 225]
  ≤ 50 g/l 7 (4.4) 2 (9.5) 5 (4.2)
  > 50 g/l 61 (38.6) 6 (28.6) 48 (40)
  > 150 g/l 90 (57) 13 (61.9) 67 (55.8)
 Hemoglobin (g/dl) 10 [7.9; 12.3] 9.8 [7.2; 10.4] 10 [8; 12.6]
  ≤ 10 g/dl 81 (51.3) 11 (52.4) 61 (50.8)
  > 10 g/dl 77 (48.7) 10 (47.6) 59 (49.2)
 Leukocytes (g/l) 10.9 [6.9; 16.4] 11.5 [8; 14.6] 10.5 [6.8; 16.3]
 PT (%) 58 [41; 75] 60 [49; 74] 58 [40; 74]
 aPTT ratio 1..4 [1.2; 1.7] 1.2 [1.1; 1.4] 1.4 [1.2; 1.8]
Hemorrhagic shock 79 (50) 8 (38.1) 64 (53.3)
 Other than hemopericardium 43 (27.2) 5 (23.8) 35 (29.2)
 Early hemopericardium 24 (15.2) 1 (4.8) 21 (17.5)
 Late hemopericardium 12 (7.6) 2 (9.5) 8 (6.7)
Number of RBC 9 [5; 19] 5 [4; 10] 12 [6; 22]
ECMO duration (days) 7.5 [4; 12] 6 [3; 8] 8 [5; 13]
Outcomes
 Bridge to VAD 10 (6.3) 2 (9.5) 8 (6.7)
 Bridge to heart transplantation 19 (12) 2 (9.5) 17 (14.2)
 ECMO weaning 80 (50.6) 17 (81) 46 (38.3)
 No weaning 49 (31) 0 (0) 49 (40.8)

Results are shown as median and interquartile ranges for quantitative variables and number and percentage for qualitative variables

*Duration of CBP and duration of aortic clampling apply only for patients who underwent CBP

AIDS acquired immuno deficiency syndrome, CBP cardiopulmonary bypass, SAPS simplified acute physiology score, SOFA sequential organ failure assessment, ALT alanine aminotransferase, AST aspartate aminotransferase, aPTT activated partial thromboplastin time, ECMO extracorporeal membrane oxygenation, ICU intensive care unit, PT prothrombin time, RBC red blood cell, VAD ventricle assistance device